Kolexia
Cartron Guillaume Hématologie
Cartron Guillaume
Hématologie
Hôpital Saint-Éloi
Montpellier, France
520 Activités
386 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Lymphome B diffus à grandes cellules Lymphome folliculaire Leucémies Maladie de Hodgkin Lymphome malin non hodgkinien Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde

Collaborateurs

Voir plus
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Le Gouill Steven
Le Gouill Steven
Clcc Institut Curie, Paris, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Roche
32 collaboration(s)
Dernière en 2023
Gilead
28 collaboration(s)
Dernière en 2023
Novartis
27 collaboration(s)
Dernière en 2023
Janssen
23 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Essai Clinique (Roche)   21 mars 2024
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
Essai Clinique (Roche)   13 mars 2024
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas: A Phase 1, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Essai Clinique (BMS)   13 mars 2024
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL): A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Essai Clinique (Celgene)   04 mars 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica   22 février 2024
Essai BICAR : de l'espoir en rechute post-CAR-T cells
Edimark   01 février 2024
Embarquez pour les journées du LYSA 2024
Edimark   01 février 2024
DALY 2-EU: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
Essai Clinique (Miltenyi Biomedicine GmbH)   31 janvier 2024